Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Efficacy and immunogenicity of recombinant swinepox virus expressing the A epitope of the TGEV S protein

Xiaomin Yuan a, Huixing Lin a, Hongjie Fan a,b,*

a College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, China
b Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou, China

ABSTRACT

To explore the possibility of developing a vaccine against transmissible gastroenteritis virus (TGEV) infection, a recombinant swinepox virus (rSPV-SA) expressing a TGEV protective antigen has been constructed. Immune responses and protection efficacy of the vaccination vector were assessed in both mice and pig models. An indirect ELISA assay suggested that when mice were vaccinated with rSPV-SA, the level of IgG against TGEV was enhanced dramatically. The cytokine assays were employed and the results indicated that both the Th1-type and Th2-type cytokine levels raised after vaccination with rSPV-SA in mice models. Results from the passive immunity protection test of new born piglets demonstrated that the recombinant live-vector vaccine, rSPV-SA, could 100% protect piglets from the SPV infection, and there was no significant clinical symptom in the rSPV-SA treatment group during this experiment. The data suggest that the novel recombinant swinepox virus is a potential vaccine against TGEV infection.

© 2015 Elsevier Ltd. All rights reserved.

1. Introduction

Transmissible gastroenteritis virus (TGEV) is a member of Coronaviridae, which is the etiological agent of transmissible gastroenteritis. Although the virus is capable of infecting swine of all ages, suckling piglets are the most susceptible and have a mortality rate up to 100% [1]. TGEV is a pleomorphic enveloped virus containing a positive-stranded RNA genome and four structural proteins: the spike (S) protein, the integral membrane (M) protein, the minor envelope (E) protein, and the nucleocapsid (N) protein. Among which, the spike (s) protein, one of the key structural membrane proteins of coronaviruses, is an attractive target for generating neutralizing antibodies against the virus due to the critical role it plays in the host cell invasion [2,3]. Precisely, the S protein mediates the attachment of virus particles to targets via binding of itself to the specific receptors. At the N terminus of the S protein, there are four antigenic sites, A, B, C, and D, which have been shown to be involved in the stimulation of neutralizing antibodies (Fig. 1) [4]. Previous studies have determined that the A site (which is fully dependent on glycosylation for proper folding) is predominantly responsible for stimulating neutralizing host antibodies [5–10].

SPV is a natural mild attenuated virus and has been widely applied as a vaccine. Given that Poxvirus-vectors can prevent a great deal of important diseases in both humans and animals it is not surprising that many of these vectors been licensed and used extensively [11–13]. Additionally, SPV is a safe vaccine vector as there is no risk of cross-species infection [14]. Therefore, both for biological and clinical practicality, SPV is regarded as an appropriate and promising veterinary vaccine for swine, owing to its ability to effectively express foreign genes, its large packaging capacity for recombinant DNA, its low cost of delivery and its specific host restriction [15]. The potential value of SPV as a live vector vaccine is being studied extensively. Because SPV is able to pack large amounts of recombinant DNA and to induce appropriate immune responses in vivo, it is a promising candidate for the development of a recombinant vaccine [16,17]. As of yet, pigs are the only known hosts of swinepox virus and therefore may be useful in developing a safe vaccine for clinical application [18,19].

In this study, we constructed a recombinant swinepox virus expressing S-A (A epitope of the S protein) of TGEV and characterized recombinant virus replication and expression of the S protein in PK-15 cells. We further investigated the potential of this approach for use in the vaccination of pigs against TGE.

2. Materials and methods

2.1. Cells and viruses

Wild type swinepox virus (wtSPV, Kasza strain, ATCC: VR363), swine testicle cells (ST, ATCC: CRL174), and porcine kidney cells (PK-15, ATCC: CCL-33) were purchased from the American
Type Culture Collection. Swine transmissible gastroenteritis virus (TGEV, China strain, SHXB) was purchased from the Jiangsu Academy of Agricultural Sciences, and the titer was determined as 1 × 10⁸ PFU/ml ST cell. TGEV convalescent positive serum was purchased from the Jiangsu Academy of Agricultural Sciences, and the neutralizing antibodies were used at a dilution of 1:10,000.

2.2. Construction and identification of the rSPV-SA plasmid

The pUSZ11 swinepox virus vector was previously generated [20]. Two primers, SA1 (5′-GGCTCGACATGCGTTCTGTATGAGCGTAG-3′) and SA2 (5′-CGGGATCCTTATAGCGTCCTGTTAGTTTGTC-3′) were used to amplify the S-A gene (516 bp, KM980444) from the TGEV genome, which was inserted into the pUSZ11 plasmid to construct pUSZ11-SA subsequently. The recombinant swinepox virus, rSPV-SA, was generated by homologous recombination of wtSPV with pUSZ11-S-A as previously described [21]. PCR and indirect immunofluorescence were employed to analyze the S-A gene expression and the expression of S protein. The replication capacity and genetic stability of rSPV-SA were also evaluated.

2.3. Generation and screening of rSPV-SA

The generation and screening of the recombinant swinepox virus assays were performed as described previously [20]. A subconfluent culture of PK-15 cells was infected with wtSPV (0.02 moi) for 2 h, and subsequently transfected with 10 μg of the pUSZ11-SA plasmid using Exfect™ Transfection Reagent (Vazyme Biotech Co., Ltd.). After 72 h, PK-15 cells were harvested and lysed by five rounds of freezing and thawing. Subsequently, the lysate was used to infect PK-15 cells grown in a 12-well plate for further purification of recombinant viruses. 1.5 ml of medium with 1% LMP agarose (DingGuo, Beijing, China) was added to each well and incubation was continued for five days until plaques became visible under a light microscope. After 1–2 days, a second overlay medium containing X-gal was added. The plaques were resuspended in 0.3 ml of medium with 2% PBS. Plaque isolation was repeated for 5–6 rounds until all plaques in a given well were stained blue. The recombinant SPV bearing S-A of TGEV was designated as rSPV-SA.

2.4. PCR analysis of the recombinant swinepox virus

The rSPV-SA genomic DNA from the PK-15 cells infected with rSPV-SA was extracted by SDS-protease K phenol. We utilized wtSPV genomic DNA from PK15 cells infected with wtSPV as a negative control. PCR was performed for 5 min at 94 °C; followed by 32 cycles of 1 min at 94 °C, 1 min at 50 °C, and 1 min at 72 °C. Amplifications were performed with DNA polymerase (Promega, Shanghai, China) using primers SA1 (5′-GGCTCGACATGCGTTCTGTATGAGCGTAG-3′) and SA2 (5′-CGGGATCCTTATAGCGTCCTGTTAGTTTGTC-3′).

2.5. Immunofluorescence assays

Indirect immunofluorescence assays (IFA) were performed as described previously [21]. PK-15 cells were grown on a 24-well plate and infected with the wtSPV and rSPV-SA at 1 × 10⁸ PFU/ml per well. PBS-treated cells were used as a negative control. At 60 h post-infection, cells were washed three times in PBS and fixed with cold methanol for 10 min at −20 °C. Cells were then washed three times with PBST and blocked by PBST with 10% BSA. Preparations were incubated for 1 h at 37 °C with TGEV convalescent positive serum (1:1000 in dilution buffer, PBST with 1% BSA). After three washes with PBST, cells were treated with the rhodamine-conjugated secondary antibody (Staphylococcal protein A-Rhod, Boshide, Wuhan, China) at a 1:5000 dilution (diluted in PBS) for 30 min at 37 °C. After a final wash with PBS, all wells were examined by fluorescence microscopy (Zeiss, Germany).

2.6. Immunization of mice and swine

Nine six-week-old BALB/C mice were randomly divided into three groups (3 mice per group), and immunized three times at 0, 14, and 28 days with rSPV-SA (1 × 10⁸ PFU/ml in 0.2 ml of PBS) or wtSPV (1 × 10⁸ PFU/ml in 0.2 ml of PBS), the control group injected with PBS.

Eight one-month-old swine (Large White) were randomly divided into four groups (2 pigs per group) and were immunized twice at 0 and 28 days with infectious rSPV-SA (1 × 10⁸ PFU/ml in 2 ml of PBS), inactivated-TGEV (1 × 10⁸ PFU/ml in 2 ml of PBS), wtSPV (1 × 10⁸ PFU/ml in 2 ml of PBS) or PBS, each time through three routes: oral, nasal, and intraperitoneal. Serum was collected 14 days after the last immunization.

Twelve one-day-old pigs were randomly divided into four groups for passive immunization experiments (3 pigs per group). High titers of antibodies were collected from piglets following the first immunization. Mouse and swine serum were incubated at 56 °C 30 min to complement inactivated.

All experimental protocols involving mice or swine were reviewed by the Laboratory Animal Monitoring Committee of Jiangsu Province.

2.7. Western blot assays

PK-15 cell monolayers were infected with wtSPV and rSPV-SA (moi of 5) and incubated for 72 h at 37 °C. Extracts, representing approximately 1 × 10⁶ cells, were electrophoresed through an SDS–12% polyacrylamide gel and the separated proteins were transferred onto a PVDF membrane. After a 2 h transfer, the membrane was blocked with 5% skim milk in phosphate buffered saline with 0.05% Tween-20 (PBST) overnight at 4 °C. The membrane was incubated with swine convalescent serum (1:1000 dilution) containing TGEV for 2 h at 37 °C and washed three times with PBS. Immunodetection was performed with staphylococcal protein A–HRP at 37 °C. Following the secondary antibody probing, the membrane was washed four times with PBS. The membrane was then developed with 3,3′-diaminobenzen-zidine substrate until optimal color development was observed.

2.8. Indirect ELISA

Serum was collected from mice and pigs, and detected the TGEV-specific antibodies by indirect ELISA. The purified TGEV was resuspended in 100 μl PBS (pH 7.2), and used the best titer of virus for coating 96-well plates, which was determined by titration. Samples were then incubated overnight at 4 °C. This incubation was followed by three PBST washes, and blocking with 5% skim milk (in PBST) at 37 °C for 2 h. Serum samples were serially diluted and...
incubated at 37 °C for 1 h. The samples were set up at the same
time and divided into three groups: the TGEV positive serum,
the negative control serum (SPV positive serum) and the blank control
(without serum). After three PBST washes, horseradish peroxidase
(HRP)-conjugated goat anti-SPA IgG (1:10,000 diluted in PBST, Sig-
nalway Antibody) was added to each test well. The plates were
then incubated at room temperature in the dark for 30 min and then
washed three times with PBST. The TMB microwell peroxidase sub-
strate system (TIANGEN) was used to develop the reaction. Samples
were developed for 20 min and the reaction terminated with 2.0 M
sulphuric acid. All assays were performed in duplicate. A microplate
reader (Bio-Rad) was used to measure the reaction product at an
absorbance of 450 nm [22].

2.9. Cytokine assay

Evaluation of cellular immunity was performed by detecting lev-
els of IFN-γ and IL-4. Three mice were sacrificed at 30 days after
the first inoculation with wtSPV (1 × 10⁹ PFU/ml in 0.2 ml), PBS or
SPV-SA (1 × 10⁸ PFU/ml in 0.2 ml). The mouse spleen was removed
aseptically. Splenocytes were isolated, counted, and diluted to a
density of 2 × 10⁷ cells/100 µl. The evenly separated cells were
diluted into 96-well plates (100 µl/well). Then, 100 µl/well of
DMEM with 200 TCID₅₀/100 µl TGEV was added to each well. After
a 60 h incubation, the supernatants were collected and the mRNA
of IFN-γ and IL-4 were probed by RT-qPCR relative to β-actin as
described previously [23,24].

2.10. Assay for neutralizing antibodies

An assay for neutralizing antibodies was performed as described
previously [18,19]. To explore whether mice or swine gen-
erated TGEV neutralizing antibodies, serum from the PBS, wtSPV,
inactivated-TGEV and rSPV-SA treated mice and pig were col-
collected at 0, 14, 21, 35, 42 days post-primary immunization
(1:100–1:12,800 dilution in a 100 µl volume). And sera were mixed
with equal volume of 100 TCID₅₀/ml TGEV and incubated at 37 °C.
After 1.5 h incubation, we utilized sera treated viruses to infect ST
cells in 96-well plates and overlaid cells with agar at 37 °C in a 5% 
CO₂ atmosphere. Cells were monitored daily for three days to detect
TGEV-specific CPE.

2.11. Protection of swine by immune serum

The virulent TGEV strain SHXB (1 × 10⁸ PFU/ml in 1 ml) was
mixed with 3 ml of the porcine antiserum induced by recombi-
nants rSPV-SA, inactivated TGEV or PBS, incubated at 37 °C for
60 min, and administered using a gastric tube to 2-day-old swine
born from TGEV-seronegative sow. Inoculated animals were fed
three times per day with formula for newborns that contained
3 ml of the antiserum. At three days following viral infection, small
intestine tissue was collected from newborn pigs sectioned for
histology. Microstructure characteristics were analyzed under the
microscope (OLYMPUS, CX21FS1, Philippines) [25].

2.12. Statistical analysis

All data were analyzed using one-way ANOVA and values of
P < 0.05 were considered significant.

3. Results

3.1. Characterization of the recombinant swinepox virus

To analyse the recombinant virus and confirm the presence of
the SA gene, two specific primers were designed to amplify the
inserted SA gene. The gene encoding the neutralizing antigen epi-
topes of TGEV is a 0.5 kb fragment and the specific fragments was
detected in VPV-SA as shown in Fig. 2A. The recombinant VPV-SA
was also confirmed by observing blue foci in plaque assays. rSPV-SA
and wtSPV were determined to be approximately 1 × 10⁸ PFU/ml
in 1 ml for both. As shown in Fig. 2B, the IFA demonstrated that
the expression of the A epitope of the S protein was present in infected cells. Western blot analysis showed a specific band of target protein with a size of 19 kDa in the cell lysates infected with rSPV-SA (Fig. 2E). The 19 kDa molecular weight is consistent with the predicted size of the SA protein of TGEV. According to these data, we suggested that the A epitope of the S protein was expressed efficiently by the rSPV-SA virus (Fig. 2).

3.2. Humoral immune responses in mice model

To monitor the S-specific antibody titers of mice vaccinated with rSPV-SA, an ELISA was used. After an initial boost 7 days post-vaccination, the S-A-specific antibody titers increased gradually in mice (Fig. 3A). The antibody titers in rSPV-SA-immunized mice were higher at all-time points post-vaccination ($P < 0.01$, $n = 5$) compared to wtSPV or PBS-treated mice. The $P/N$ value of the positive group was greater than 2.1. Persistent high levels of neutralizing antibodies (Fig. 4A) were detected in the rSPV-SA group with a mean titer of 1:1000 at 42 days post-inoculation.

3.3. Cellular immune responses in mice

In mice vaccinated with wtSPV and rSPV-SA at 30 days post-inoculation (Fig. 3B), the qPCR results showed a distinct variation of IL-4 and IFN-γ between wtSPV and rSPV-SA treatment groups. The relative quantity normalized by beta-actin of IL-4 mRNA in rSPV-SA was 1.47 times higher compared to wtSPV. The IFN-γ mRNA levels increased 1.45 fold in rSPV-SA when compared to wtSPV. The concentrations of IL-4 and IFN-γ in rSPV-SA-vaccinated mice were significantly higher than the control groups. These results indicate that rSPV-SA induces Th1-type and Th2-type cytokine responses during cellular immunity.

3.4. Safety of rSPV-SA in pigs

During the vaccination procedure, several poxes of 2 mm in diameter were observed around the injection position at five days post-inoculation in both rSPV-SA and wtSPV treatment groups, respectively, which was not observed in the inactivated-TGEV and PBS treatment groups. This symptom could be disappeared spontaneously in the following 5 days. No pigs developed further symptoms such as fever or severe inflammation, and the spiritual condition and appetite of both treatment groups was considered as good. These two group pigs recovered in 14 days. All group pigs maintained rectal temperatures of 38.7–39.3 °C. From this experiment, we reveal that vaccination with rSPV-SA and wtSPV is well tolerated by pigs.

3.5. Neutralizing antibody production in swine

rSPV-SA induced a moderate level of TGEV-specific IgG as shown in Fig. 5. Persistent high levels of TGEV-specific neutralizing antibodies are shown in Fig. 4b. The second boost led to of the levels
of TGEV-specific neutralizing antibodies. Persistent high levels of neutralizing antibodies were detected in the rSPV-SA group at a mean titer of 1:1400 in swine ($P < 0.05, n = 5$).

### 3.6. Passive immunity

All newborn piglets in different groups were fed with the mixture of TGEV and the corresponding sera from pigs vaccinated with PBS, wtSPV, inactivated-TGEV, or rSPV-SA. Both PBS and wtSPV treatment groups developed a very severe diarrhea symptom, significantly losing of weight and appetite, and the mortality rate was up to 100% in 3 days. Meanwhile, in the inactivated-TGEV and rSPV-SA treatment groups, there was no obvious clinical symptoms and 0% mortality rate observed (Fig. 6, and Table 1). After the sacrificing of all the piglets, the small intestine tissue from different groups were used for the pathological examination. Histological samples from PBS and wtSPV treatment groups showed prominent histopathological changes in the small intestine characterized by serious fracture of the small intestine mucosa, epithelial expansion, vacuolar degeneration, necrosis, shredding, and lamina propria congestive edema and hemorrhage. And such pathological changes were not observed during the examination of the samples from inactivated-TGEV and rSPV-SA treatment groups. All the results indicate that rSPV-SA inoculation provides complete protection passive immunity against TGEV challenge in pigs (Fig. 7).

### 4. Discussion

In the present study, we have engineered the swinepox virus to express the A epitope of the TGEV S protein. Our data showed that this recombinant virus was not only able to induce a strong immune response against the A antigen of TGEV in mice and pigs, but also had safety degree and protection efficacy against the virulent homologous TGEV infection in pigs. The traditional way to protect swine from TGEV infection is to immunize pregnant sows with inactivated or attenuated vaccine, resulting in the production of Secretory IgA in the colostrum. Despite the protection that Secretory IgA offers piglets, this method does not provide protection after the cessation of breastfeeding. Furthermore, inactivated or attenuated viral vaccines still maintain the ability of developing the viral toxicity [26]. Currently, there are various potential vaccines against TGEV but many present certain challenges, such as difficulties in the vaccination process, high production cost, low immunogenicity, biological risk and carcinogenicity.

The results from our experiments indicate that the rSPV-SA vaccine is a very promising candidate in the safety and immunogenicity respect. However, it should be noticed that, as an alive viral vector vaccine, it is possible that the SPV per se would interfere the vaccination. To evaluate this possibility, 2000 randomly sampled pig sera were tested via the agarose gel diffusion assay, and the results showed the SPV positive rate was around 1%. Moreover, there was no report of SPV epidemic in these recent years. Thus, together with gel diffusion assay, the interfering from SPV per se could be considered as minimum.

For the first time, we generated a recombinant SPV that expresses the neutralizing epitopes (A epitope in Protein S) of TGEV, and we verified that the S-A was expressed efficiently in our system. The antigen induced neutralizing antibodies against TGEV in ST cells, and potentiated strong TH1-type and TH2-type cytokine responses in our mouse model. These results suggest that rSPV-SA induces humoral and cellular immune responses effectively and efficiently. Given the Th1 cell secretion of IL-2, IFN-γ, IFN-α, and TNF-β, it is apparent that Th1 cells play an important role in anti-intracellular pathogenic infection. Because Th2 cells in our study secreted IL-4, IL-5, IL-6 and IL-10, it is likely that these cells were able to effectively stimulate B cell proliferation and hence, IgG and IgE antibody production (relevant to humoral immunity). We defined IFN-γ and IL-4 to be representative of the Th1-type and Th2-type cytokine secretory capacity, respectively. Our results indicate that in our hands, both TH1-type and TH2-type cytokine levels increased dramatically.

Due to the immature immune system, the maternal antibodies from breast milk account for the immune defensive ability of

### Table 1

| Sow group         | 12 h  | 24 h  | 36 h  | 48 h  |
|-------------------|-------|-------|-------|-------|
|                   | a     | b     | c (%) | a     | b     | c (%) | a     | b     | c (%) | a     | b     | c (%) |
| rSPV-SA           | −     | −     | 0     | −     | −     | 0     | −     | −     | 0     | −     | −     | 0     |
| Inactivated-TGEV  | +     | 33    | ++    | +     | 33    | ++    | +     | 33    | ++    | +     | 33    |
| PBS               | +     | 33    | ++    | +     | 66    | ++    | +     | 66    | ++    | +     | 100   |
| wtSPV             | +     | 33    | ++    | +     | 66    | ++    | +     | 66    | ++    | +     | 100   |

(a) −, no diarrhea; +, mild diarrhea; ++, severe diarrhea. (b) TGEV in feces was detected using RT-PCR. (c) Mortality attributed to TGEV infection.
piglets. Based on the feasibility and relevant published papers [25], we decided to mimic the breast milk from female pig by mixing the anti-serum generated by vaccinating the 30 days old piglets with SPV-SA and the normal cow milk, and use it for passive immunity protection test on the 1days old piglets. In the study, the recombinant SPV vectors were capable of protecting neonatal piglets against mortality and severe disease after a challenge with virus. The rSPV-SA vector induced high titers of antibodies in swine. However it is worth noting that rSPV-SA may enhance the anti-TGEV antibody titer in swine as well as the anti-SPV antibody, which will likely affect immune efficiency. With respect to clinical value, it is imperative to study this multivalent vaccine.

To summarize, we first report that SPV can be used as a live vector vaccine when it expresses the S-A protein of TGEV. We determined that not only B-cells, but also T-cells were induced successfully. Thus, rSPV-SA provides thorough protection against virulent TGEV challenge in swine. Lastly, our data indicate that rSPV-SA is a promising vaccine to prevent TGEV infection.

Conflict of interest statement

The authors of this paper have no financial or personal relationship with other people or organizations that could inappropriately influence or bias the content of the paper.

Acknowledgments

This study was supported by Program from the National Basic Research Program (973) of China (2012CB518804), the National Transgenic Major Program (2014ZX08009-046B), Special Fund for Agro-scientific Research in the Public Interest (201403054), the Jiangsu Province Science and Technology Support Program (BE2013433), the Jiangsu Agriculture Science and Technology Innovation Fund (CX(15)1056) and the Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions.

References

[1] Schwegmann-Wessels C, Herrler G. Transmissible gastroenteritis virus infection: a vanishing specter. Dtsch Tierarztl Wochenschr 2006;113:157–9.
[2] Spaan W, Cavanagh D, Horzinek MC. Coronaviruses: structure and genome expression. J Gen Virol 1988;69(Pt 12):2939–52.
[3] Delmas B, Geff J, Laude H. Antigenic structure of transmissible gastroenteritis virus. II. Domains in the peplomer glycoprotein. J Gen Virol 1986;67(Pt 7):1405–18.
[4] Meng F, Zhao Z, Li G, Soso S, Shi N, Yin J, et al. Bacterial expression of antigenic sites A and D in the spike protein of transmissible gastroenteritis virus and evaluation of their inhibitory effects on viral infection. Virus Genes 2011;43:335–41.
[5] Meng F, Ren Y, Soso S, Sun X, Li X, Li P, et al. Evaluation on the efficacy and immunogenicity of recombinant DNA plasmids expressing spike genes from porcine transmissible gastroenteritis virus and porcine epidemic diarrhea virus. PLoS ONE 2013;8:e57468.
[6] Yang H, Liu J, Cao S, Huang X, Wen X. Construction, safety and immunogenicity analysis of attenuated Salmonella typhimurium harbouring TGEV DNA vaccine. Wei Sheng Wu Xue Bao 2009;49:72–7.
[7] Correa L, Gebauer F, Bullido MJ, Sune C, Baay MF, Zwaagstra KA, et al. Localization of antigenic sites of the E2 glycoprotein of transmissible gastroenteritis coronavirus. J Gen Virol 1990;71(Pt 2):271–9.
[8] Laviada MD, Videgain SP, Moreno L, Alonso F, Enjuanes L, Escripon JM. Expression of swine transmissible gastroenteritis virus envelope antigens on the surface of infected cells: epitopes externally exposed. Virus Res 1990;16:247–54.
[9] Moxley RA, Olson LD. Clinical evaluation of transmissible gastroenteritis virus vaccines and vaccination procedures for inducing lactogenic immunity in sows. Am J Vet Res 1989;50:111–8.
[10] Zhao Q, Zhu J, Zhu W, Li X, Tao Y, Lv X, et al. A monoclonal antibody against transmissible gastroenteritis virus generated via immunization of a DNA plasmid bearing TGEV S1 gene. Monoclon Antib Immunodiot Immunother 2013;32:50–4.
[11] Vincor F, Jack Jr L. 25 years and counting: Centers for Disease Control and Prevention identifies opportunities and challenges for diabetes prevention and control. Ann Intern Med 2004;140:943–4.
[12] Pastoret PP, Broschier B. Development of a recombinant vaccinia-rabies vaccine for oral vaccination of foxes against rabies. Dev Biol Stand 1992;79:105–11.
[13] Taylor J, Weinberg R, Desmettre P, Paoloeti E. Recombinant fowlpox virus inducing protective immunity in non-avian species. Vaccine 1988;6:497–503.
[14] Barcena J, Blasco R. Recombinant swinepox virus expressing beta-galactosidase: investigation of viral host range and gene expression levels in cell culture. Virology 1998;243:396–405.
[15] Hahn J, Park SH, Song JY, An SH, Ahn BY. Construction of recombinant swinepox viruses and expression of the classical swine fever virus E2 protein. J Virol Methods 2001;93:49–56.
[16] Winslow BJ, Cochran MD, Holzenburg A, Sun J, Junker DE, Colisson EW. Replication and expression of a swinepox virus vector delivering feline leukemia virus Gag and Env to cell lines of swine and feline origin. Virus Res 2003;98:1–15.
[17] Winslow BJ, Kalabat DY, Brown SM, Cochran MD, Colisson EW. Feline B7.1 and B7.2 proteins produced from swinepox virus vectors are natively processed and biologically active: potential for use as nonchemical adjuvants. Vet Microbiol 2005;111:1–13.
[18] Huang D, Zhu H, Lin H, Xu J, Lu C. First insights into the protective effects of a recombinant swinepox virus expressing truncated MRP of Streptococcus suis type 2 in mice. Berl Munch Tierarztl Wochenschr 2012;125:144–52.

[19] Xu J, Huang D, Liu S, Lin H, Zhu H, Liu B, et al. Immune responses and protection efficacy of a recombinant swinepox virus expressing HA1 against swine H3N2 influenza virus in mice and pigs. Virus Res 2012;167:188–95.

[20] Lin HX, Huang DY, Wang Y, Lu CP, Fan HJ. A novel vaccine against Streptococcus equi ssp. zooepidemicus infections: the recombinant swinepox virus expressing M-like protein. Vaccine 2011;29:7027–34.

[21] Soprana E, Panigada M, Knauf M, Radaelli A, Vigevani L, Palini A, et al. Joint production of prime/boost pairs of Fowlpox Virus and modified Vaccinia Ankara recombinants carrying the same transgene. J Virol Methods 2011;174:22–8.

[22] Tang M, Harp JA, Wesley RD. Recombinant adenovirus encoding the HA gene from swine H3N2 influenza virus partially protects mice from challenge with heterologous virus: A/HK/1/68 (H3N2). Arch Virol 2002;147:2125–41.

[23] Zheng Q, Chen D, Li P, Bi Z, Cao R, Zhou B, et al. Co-expressing GPS and M proteins under different promoters in recombinant modified vaccinia virus ankara (rMVA)-based vaccine vector enhanced the humoral and cellular immune responses of porcine reproductive and respiratory syndrome virus (PRRSV). Virus Genes 2007;35:585–95.

[24] Mattei LM, Cotmore SF, Tattersall P, Iwasaki A. Parvovirus evades interferon-dependent viral control in primary mouse embryonic fibroblasts. Virology 2013;442:20–7.

[25] Torres JM, Sanchez C, Sune C, Smerdou C, Prevec L, Graham F, et al. Induction of antibodies protecting against transmissible gastroenteritis coronavirus (TGEV) by recombinant adenovirus expressing TGEV spike protein. Virology 1995;213:503–16.

[26] Tang L, Li Y. Oral immunization of mice with recombinant Lactococcus lactis expressing porcine transmissible gastroenteritis virus spike glycoprotein. Virus Genes 2009;39:238–45.